Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)

[1]  Caillot,et al.  Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study , 1998, British journal of haematology.

[2]  M. Lazzarino,et al.  Randomized clinical study comparing aggressive chemotherapy with or without G‐CSF support for high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS , 1998, British journal of haematology.

[3]  J. Sosman,et al.  A phase II trial of interleukin‐2 in myelodysplastic syndromes , 1998, British journal of haematology.

[4]  S. Feig,et al.  Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. , 1998, Journal of Clinical Oncology.

[5]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[6]  K. Sullivan,et al.  Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia , 1996, British journal of haematology.

[7]  G. Verhoef,et al.  Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor‐risk myelodysplastic syndromes , 1996, British journal of haematology.

[8]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[9]  J. Brieger,et al.  Bone marrow-derived T-cell clones obtained from untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity. , 1995, Leukemia research.

[10]  R. Foà,et al.  Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. , 1994, Blood.

[11]  F. Appelbaum,et al.  Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. , 1993, Blood.

[12]  Klingemann Hg,et al.  Response of therapy-related myelodysplasia to low-dose interleukin-2. , 1993 .

[13]  E. Berman,et al.  Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. , 1992, Blood.

[14]  Janice Gabrilove,et al.  Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .

[15]  R. Foà,et al.  Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study , 1991, British journal of haematology.

[16]  E. Archimbaud,et al.  Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance , 1991, British journal of haematology.

[17]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[18]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[19]  M. Cazzola,et al.  A patient-oriented approach to treatment of myelodysplastic syndromes. , 1998, Haematologica.

[20]  A. Ganser,et al.  A Randomized , Double-Blind , Placebo-Controlled , Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .

[21]  D. Scheinberg,et al.  Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. , 1996, Leukemia.

[22]  L. Bergmann,et al.  Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. , 1995, Leukemia & lymphoma.

[23]  H. Klingemann,et al.  Response of therapy-related myelodysplasia to low-dose interleukin-2. , 1993, Leukemia.

[24]  J. Matthews,et al.  Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. , 1990, Blood.